Linked videos:
• TDM-105795 - a new ha...
• New research shows HMI...
• Why HMI-115 will be a ...
• Update on HMI-115 for ...
• Pyrilutamide phase III...
Sources:
1. Inc HM. Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia. Accessed January 15, 2024. www.prnewswire.com/news-relea...
2. Medicines T. Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial. Accessed June 4, 2023. www.prnewswire.com/news-relea...
3. Medicines T. Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia. Accessed February 6, 2024. www.prnewswire.com/news-relea...
4. Randall VA, Ebling FJ. Seasonal changes in human hair growth. Br J Dermatol. 1991;124(2):146-151. doi:10.1111/j.1365-2133.1991.tb00423.x
5. Billoni N, Buan B, Gautier B, Gaillard O, Mahé YF, Bernard BA. Thyroid hormone receptor beta1 is expressed in the human hair follicle. Br J Dermatol. 2000;142(4):645-652. doi:10.1046/j.1365-2133.2000.03408.x
6. Miller FG, Colloca L, Kaptchuk TJ. The placebo effect: illness and interpersonal healing. Perspectives in biology and medicine. 2009;52(4):518. doi:10.1353/pbm.0.0115
7. Li JJ, Mitchell LH, Dow RL. Thyroid receptor agonists for the treatment of androgenetic alopecia. Bioorg Med Chem Lett. 2010;20(1):306-308. doi:10.1016/j.bmcl.2009.10.109
8. Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16(3):233-248. doi:10.1007/s11154-015-9322-3
9. Hernandez I, Bott SW, Patel AS, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018;24(2):109-112.
10. Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. In: StatPearls. StatPearls Publishing; 2024. Accessed February 7, 2024. www.ncbi.nlm.nih.gov/books/NBK...
Негізгі бет Тәжірибелік нұсқаулар және стиль TDM-105795, a new hair loss treatment that actually works!
Пікірлер: 530